Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma

Study:

Feasibility/Phase II Study of hu14.18-IL2 Immunocytokine + GM-CSF and Isotretinoin in Patients With Relapsed or Refractory Neuroblastoma

Rationale:

Biological therapy and sargramostim, work in different ways to stimulate the immune system and stop tumor cells from growing. Drugs used in chemotherapy, such as isotretinoin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving biological therapy together with sargramostim and isotretinoin may kill more tumor cells.

Purpose:

This phase II trial is studying how well biological therapy works when given together with sargramostim and isotretinoin in treating patients with relapsed or refractory neuroblastoma.

Study Status: Suspended

Recruiting:
n/a

Condition Intervention Phase
Neuroblastoma Biological: hu14.18-IL2 fusion protein
Biological: sargramostim
Drug: isotretinoin
Other: laboratory biomarker analysis		 Phase 2

Verified by Children`s Oncology Group August, 2012

Sponsored by: Children`s Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT01334515

Study Type: Interventional

Study Design: Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Suzanne Shusterman, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.